UK opens long-awaited inquiry into tainted blood scandal
LONDON (AP) — A long-awaited inquiry has opened in Britain into how contaminated blood was used to treat thousands of people in the 1970s and ’80s, killing at least 2,400.
Thousands of British public health patients — many of them hemophiliacs — were infected with HIV or Hepatitis C ...
New corn maze seeks to raise awareness of blood disorder
JOHNSTON, R.I. (AP) — A new corn maze in Johnston is raising awareness of hemophilia and other blood disorders.
Salisbury Farm unveiled the maze Saturday and says it will donate part of its proceeds to the New England Hemophilia Association.
BANGOR, Maine (AP) — A number of cocktail makers in Bangor will be battling it out for the honor of the “best” bloody mary cocktail.
The inaugural competition may get heated, but it’s all for a great cause — proceeds will benefit the Hemophilia Alliance of Maine. WABI-TV
France’s Sanofi buys US hemophilia specialist Bioverativ
PARIS (AP) — France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.
The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing ...
Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.
Hemophilia almost always strikes males and is caused by lack of a gene that ...
TRENTON, N.J. (AP) — Could there be a second life for the once-popular arthritis pill Vioxx? A startup pharmaceutical company hopes so.
Merck & Co. voluntarily pulled the blockbuster drug in 2004 amid evidence that it doubled the chances of having a heart attack or stroke.
TRENTON, N.J. (AP) — The Latest on the possible return of Vioxx (all times local):
Could the once-popular arthritis pill Vioxx (VEYE-ochs) get a second life? A startup pharmaceutical company hopes so.
In 2004, Merck & Co. voluntarily pulled the blockbuster drug ...
TRENTON, N.J. (AP) — U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia.
The Food and Drug Administration on Thursday approved Hemlibra, a weekly self-injection for hemophilia A patients who have ...
NASHVILLE, Tenn. (AP) — A judge is letting a lawsuit continue that claims Tennessee is breaking federal law and endangering people with bleeding disorders like hemophilia by reimbursing less for prescription blood-clotting drugs through its Medicaid program.
Last week, Davidson County ...
NASHVILLE, Tenn. (AP) — Pharmacies in Tennessee are accusing the state of breaking federal law and endangering people with bleeding disorders such as hemophilia by reducing reimbursements for prescription blood-clotting drugs through its Medicaid program.
Hemophilia is very rare, affecting ...
LONDON (AP) — British Prime Minister Theresa May on Tuesday ordered a public inquiry into how contaminated blood was used to treat thousands of people in the 1970s and ’80s, killing at least 2,400, according to officials.
Thousands of British public health patients — many of them ...
Scientists at the Center for Cardiovascular Research at the University of Hawaii John A. Burns School of Medicine hope that patients with hemophilia could one day be treated with gene therapy delivered by tiny bubbles.
The technique could provide an alternative to current treatments for ...
BOSTON (AP) — Massachusetts lawmakers are joining an effort to bring attention to the plight of hemophilia patients.
The New England Hemophilia Association says the Legislature adopted a resolution that declares March as bleeding disorders awareness month in the state.
The group says ...
- Business WireHemophilia B - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.comFebruary 15, 2019
- Globe NewswireCatalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD CongressFebruary 8, 2019
- Globe NewswireCatalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia BFebruary 6, 2019
- Business WireTakeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia A– at EAHAD 2019February 6, 2019
- Business WireTogether with Roche, Chugai Joins the World Federation of Hemophilia Humanitarian Aid ProgramFebruary 6, 2019